+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study

Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study

Journal of Neurology 255(7): 1032-1037

Objective To investigate the sleep-wake cycle and the effects of cabergoline monotherapy in a homogenous group of de novo Parkinson's Disease (PD) patients without confounding comorbid factors. Design and participants Twelve de novo patients affected by idiopathic PD underwent two ambulatory polysomnographic (APSG) monitoring sessions. The first was performed at baseline, and the second recording one-month after stable treatment with cabergoline monotherapy. Subjective daytime sleepiness was evaluated by means of the Epworth Sleepiness Scale. Data obtained in PD patients at baseline were compared with those obtained in 12 age- and sex-matched healthy subjects. Results Diurnal sleep parameters did not show significant differences between controls and PD patients at baseline. In PD patients, no significant changes in diurnal sleep were observed between baseline and cabergoline treatment. Regarding nocturnal sleep, patients at baseline showed a significantly lower sleep efficiency and a significantly higher Wakefulness After Sleep Onset than controls. With respect to baseline, a significant increase in REM latency and a significant reduction in REM sleep were observed during cabergoline treatment. Conclusions In the early stage of PD, the neurodegenerative process does not seem to be directly responsible for daytime somnolence, but it may be directly involved in the alteration of nocturnal sleep. Cabergoline monotherapy does not affect daytime sleep propensity and, despite clinical improvement, it may have negative effects on REM sleep.

(PDF emailed within 0-6 h: $19.90)

Accession: 033411424

Download citation: RISBibTeXText

PMID: 18500498

DOI: 10.1007/s00415-008-0836-4

Related references

Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study. Journal of Neural Transmission 113(12): 1909-1913, 2006

Effects of pregabalin on sleep-wake cycle in epilepsy patients: A polysomnographic study. 2007

Effects of zonisamide as add-on therapy on sleep-wake cycle in focal epilepsy: a polysomnographic study. Epilepsy & Behavior 26(2): 170-174, 2013

Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study. Neurology 59(12): 1979-1981, 2002

Progressive sleep 'destructuring' in Parkinson's disease. A polysomnographic study in 46 patients. Sleep Medicine 6(4): 313-318, 2005

An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease. Sleep & Breathing, 2016

The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 28(10): 1866-1870, 2003

A Polysomnographic Study of Parkinson's Disease Sleep Architecture. Parkinson's Disease 2015: 570375-570375, 2015

Sleep attacks in Parkinson's disease: a clinical and polysomnographic study. Neurological Sciences 24(3): 195-196, 2003

Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances. Wiener Klinische Wochenschrift 113(7-8): 249-253, 2001

Hallucinations and sleep-wake cycle in Alzheimer's disease: a questionnaire-based study in 218 patients. Neurological Sciences 28(2): 96-99, 2007

Prevalence and correlates of sleep disorders in Parkinson's disease: a polysomnographic study. Arquivos de Neuro-Psiquiatria 73(3): 241-245, 2015

Sleep Disturbances in Essential Tremor and Parkinson Disease: A Polysomnographic Study. Journal of Clinical Sleep Medicine 11(6): 655-662, 2016

A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. Neurology 50(5): 1332-1339, 1998

Changes in characteristics of sleep-wake cycle and motor activity at the preclinical stage of Parkinson's disease in old rats. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 118(4. Vyp. 2): 14-20, 2018